GB201116092D0 - Antibodies and uses thereof - Google Patents

Antibodies and uses thereof

Info

Publication number
GB201116092D0
GB201116092D0 GBGB1116092.6A GB201116092A GB201116092D0 GB 201116092 D0 GB201116092 D0 GB 201116092D0 GB 201116092 A GB201116092 A GB 201116092A GB 201116092 D0 GB201116092 D0 GB 201116092D0
Authority
GB
United Kingdom
Prior art keywords
human
antibodies
lymphocytes
specifically bind
teffs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1116092.6A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIOCEROS BV
Original Assignee
BIOCEROS BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44937444&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB201116092(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by BIOCEROS BV filed Critical BIOCEROS BV
Priority to GBGB1116092.6A priority Critical patent/GB201116092D0/en
Publication of GB201116092D0 publication Critical patent/GB201116092D0/en
Priority to MDA20140039A priority patent/MD4578C1/ro
Priority to US14/345,222 priority patent/US9475880B2/en
Priority to JP2014530314A priority patent/JP6212493B2/ja
Priority to HK15102317.5A priority patent/HK1201852B/xx
Priority to SG11201400706SA priority patent/SG11201400706SA/en
Priority to EA201490484A priority patent/EA031006B1/ru
Priority to UAA201404032A priority patent/UA115316C2/uk
Priority to KR1020147010124A priority patent/KR20140069172A/ko
Priority to MX2014003156A priority patent/MX352495B/es
Priority to PE2014000359A priority patent/PE20141546A1/es
Priority to EA201890934A priority patent/EA201890934A1/ru
Priority to IN2535CHN2014 priority patent/IN2014CN02535A/en
Priority to PH1/2014/500598A priority patent/PH12014500598A1/en
Priority to SG10201608872VA priority patent/SG10201608872VA/en
Priority to MDA20170082A priority patent/MD4612C1/ro
Priority to PCT/GB2012/052268 priority patent/WO2013038191A2/en
Priority to CA2848847A priority patent/CA2848847A1/en
Priority to MYPI2014700626A priority patent/MY185448A/en
Priority to EP12775045.3A priority patent/EP2756001A2/en
Priority to CN201280056242.1A priority patent/CN104080809B/zh
Priority to NZ623840A priority patent/NZ623840B2/en
Priority to EP18167594.3A priority patent/EP3409689A1/en
Priority to AU2012308155A priority patent/AU2012308155B2/en
Priority to BR112014006158A priority patent/BR112014006158A2/pt
Priority to CN201710269930.0A priority patent/CN107722123A/zh
Priority to NZ718372A priority patent/NZ718372B2/en
Priority to GT201400051A priority patent/GT201400051A/es
Priority to CL2014000631A priority patent/CL2014000631A1/es
Priority to IL231540A priority patent/IL231540B/en
Priority to ZA2014/01939A priority patent/ZA201401939B/en
Priority to ECSP14013259 priority patent/ECSP14013259A/es
Priority to CO14060426A priority patent/CO7020859A2/es
Priority to CR20140146A priority patent/CR20140146A/es
Priority to ZA2015/02860A priority patent/ZA201502860B/en
Priority to US15/247,425 priority patent/US20170051069A1/en
Priority to CL2016002816A priority patent/CL2016002816A1/es
Priority to AU2017202564A priority patent/AU2017202564B2/en
Priority to US15/986,565 priority patent/US20180273632A1/en
Priority to HK18109300.6A priority patent/HK1249909A1/zh
Priority to IL266608A priority patent/IL266608A/en
Priority to PH12019501115A priority patent/PH12019501115A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB1116092.6A 2011-09-16 2011-09-16 Antibodies and uses thereof Ceased GB201116092D0 (en)

Priority Applications (42)

Application Number Priority Date Filing Date Title
GBGB1116092.6A GB201116092D0 (en) 2011-09-16 2011-09-16 Antibodies and uses thereof
CN201710269930.0A CN107722123A (zh) 2011-09-16 2012-09-13 抗cd134(ox40)抗体及其应用
NZ718372A NZ718372B2 (en) 2011-09-16 2012-09-13 Anti-cd134 (ox40) antibodies and uses thereof
EP12775045.3A EP2756001A2 (en) 2011-09-16 2012-09-13 Anti-cd134 (ox40) antibodies and uses thereof
NZ623840A NZ623840B2 (en) 2011-09-16 2012-09-13 Anti-cd134 (ox40) antibodies and uses thereof
AU2012308155A AU2012308155B2 (en) 2011-09-16 2012-09-13 Anti-CD134 (OX40) antibodies and uses thereof
HK15102317.5A HK1201852B (en) 2011-09-16 2012-09-13 Anti-cd134 (ox40) antibodies and uses thereof
SG11201400706SA SG11201400706SA (en) 2011-09-16 2012-09-13 Anti-cd134 (ox40) antibodies and uses thereof
EA201490484A EA031006B1 (ru) 2011-09-16 2012-09-13 Антитела против cd134 (ox40) и их применение
UAA201404032A UA115316C2 (uk) 2011-09-16 2012-09-13 Зв'язувальна молекула, яка зв'язується з cd134 людини, та фармацевтична композиція, що її містить
KR1020147010124A KR20140069172A (ko) 2011-09-16 2012-09-13 항­ｃｄ １３４（ｏｘ４０） 및 이의 용도
MX2014003156A MX352495B (es) 2011-09-16 2012-09-13 Anticuerpos anti-cd134 (ox40) y usos de los mismos.
PE2014000359A PE20141546A1 (es) 2011-09-16 2012-09-13 Anticuerpos anti-cd134(ox40) y sus usos de los mismos
EA201890934A EA201890934A1 (ru) 2011-09-16 2012-09-13 Антитела против cd134 (ox40) и их применение
IN2535CHN2014 IN2014CN02535A (enExample) 2011-09-16 2012-09-13
PH1/2014/500598A PH12014500598A1 (en) 2011-09-16 2012-09-13 Anti-cd134 (ox40) antibodies and uses thereof
SG10201608872VA SG10201608872VA (en) 2011-09-16 2012-09-13 Anti-cd134 (ox40) antibodies and uses thereof
MDA20170082A MD4612C1 (ro) 2011-09-16 2012-09-13 Anticorpi anti-CD134 (OX40) şi aplicarea acestora
PCT/GB2012/052268 WO2013038191A2 (en) 2011-09-16 2012-09-13 Anti-cd134 (ox40) antibodies and uses thereof
CA2848847A CA2848847A1 (en) 2011-09-16 2012-09-13 Anti-cd134 (ox40) antibodies and uses thereof
MYPI2014700626A MY185448A (en) 2011-09-16 2012-09-13 Anti-cd134 (ox40) antibodies and uses thereof
MDA20140039A MD4578C1 (ro) 2011-09-16 2012-09-13 Anticorpi anti-CD134 (OX40) şi aplicarea acestora
CN201280056242.1A CN104080809B (zh) 2011-09-16 2012-09-13 抗cd134(ox40)抗体及其应用
EP18167594.3A EP3409689A1 (en) 2011-09-16 2012-09-13 Anti-cd134 (ox40) antibodies and uses thereof
US14/345,222 US9475880B2 (en) 2011-09-16 2012-09-13 Anti-CD134 (OX40) antibodies and uses thereof
JP2014530314A JP6212493B2 (ja) 2011-09-16 2012-09-13 抗ｃｄ１３４（ｏｘ４０）抗体およびその使用
BR112014006158A BR112014006158A2 (pt) 2011-09-16 2012-09-13 molécula de ligação, molécula de ácido nucléico, vetor, célula hospedeira, processo para preparar uma molécula de ligação, métodos para acentuar uma resposta imune em um indivíduo humano, para tratar câncer em um indivíduo humano em necessidade do mesmo, para reduzir o tamanho de um tumor ou inibir o crescimento de células cancerosas em um indivíduo ou reduzir ou inibir o desenvolvimento do câncer metastático em um indivíduo sofrendo de câncer, uso de uma molécula de ligação, e, composição farmacêutica
CL2014000631A CL2014000631A1 (es) 2011-09-16 2014-03-14 Molecula de union que se une a cd134 (ox40); molecula de acido nucleico que la codifica; vector; celula huesped; proceso de preparacion; composicion farmaceutica que la comprende; y su uso para tratar cancer.
GT201400051A GT201400051A (es) 2011-09-16 2014-03-14 Anticuerpos anti-cd134 (ox40) y usos de los mismos
IL231540A IL231540B (en) 2011-09-16 2014-03-16 Anti-(40ox)134cd antibodies and their uses
ZA2014/01939A ZA201401939B (en) 2011-09-16 2014-03-17 Anti-cd134 (ox40) antibodies and uses thereof
ECSP14013259 ECSP14013259A (es) 2011-09-16 2014-03-19 Anticuerpos anti-cd134 (ox40) y usos de los mismos
CO14060426A CO7020859A2 (es) 2011-09-16 2014-03-20 Anticuerpos anti-cd134 (ox40) y usos de los mismos
CR20140146A CR20140146A (es) 2011-09-16 2014-04-01 Anticuerpos anti-cd134 (ox40) y usos de los mismos
ZA2015/02860A ZA201502860B (en) 2011-09-16 2015-04-24 Anti-cd134 (ox40) antibodies and uses thereof
US15/247,425 US20170051069A1 (en) 2011-09-16 2016-08-25 Anti-cd134 (ox40) antibodies and uses thereof
CL2016002816A CL2016002816A1 (es) 2011-09-16 2016-11-07 Anticuerpos anti-cd 134 (ox40) y usos de los mismos (divisional de sol. n° 631-14).
AU2017202564A AU2017202564B2 (en) 2011-09-16 2017-04-19 Anti-CD134 (OX40) antibodies and uses thereof
US15/986,565 US20180273632A1 (en) 2011-09-16 2018-05-22 Anti-cd134 (ox40) antibodies and uses thereof
HK18109300.6A HK1249909A1 (zh) 2011-09-16 2018-07-18 抗cd134(ox40)抗体及其应用
IL266608A IL266608A (en) 2011-09-16 2019-05-14 Anti-CD134 (OX40) antibodies and their uses
PH12019501115A PH12019501115A1 (en) 2011-09-16 2019-05-17 Anti-cd134 (ox40) antibodies and uses thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1116092.6A GB201116092D0 (en) 2011-09-16 2011-09-16 Antibodies and uses thereof

Publications (1)

Publication Number Publication Date
GB201116092D0 true GB201116092D0 (en) 2011-11-02

Family

ID=44937444

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1116092.6A Ceased GB201116092D0 (en) 2011-09-16 2011-09-16 Antibodies and uses thereof

Country Status (27)

Country Link
US (3) US9475880B2 (enExample)
EP (2) EP3409689A1 (enExample)
JP (1) JP6212493B2 (enExample)
KR (1) KR20140069172A (enExample)
CN (2) CN107722123A (enExample)
AU (2) AU2012308155B2 (enExample)
BR (1) BR112014006158A2 (enExample)
CA (1) CA2848847A1 (enExample)
CL (2) CL2014000631A1 (enExample)
CO (1) CO7020859A2 (enExample)
CR (1) CR20140146A (enExample)
EA (2) EA031006B1 (enExample)
EC (1) ECSP14013259A (enExample)
GB (1) GB201116092D0 (enExample)
GT (1) GT201400051A (enExample)
HK (1) HK1249909A1 (enExample)
IL (2) IL231540B (enExample)
IN (1) IN2014CN02535A (enExample)
MD (2) MD4578C1 (enExample)
MX (1) MX352495B (enExample)
MY (1) MY185448A (enExample)
PE (1) PE20141546A1 (enExample)
PH (2) PH12014500598A1 (enExample)
SG (2) SG11201400706SA (enExample)
UA (1) UA115316C2 (enExample)
WO (1) WO2013038191A2 (enExample)
ZA (2) ZA201401939B (enExample)

Families Citing this family (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME02678B (me) 2010-08-23 2017-06-20 Univ Texas Antitijela na ox-40 i postupci njihove primjene
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
PL2925350T3 (pl) 2012-12-03 2019-07-31 Bristol-Myers Squibb Company Zwiększenie aktywności przeciwnowotworowej immunomodulacyjnych białek fuzyjnych fc
UA119319C2 (uk) 2013-03-18 2019-06-10 Біосерокс Продактс Б.В. Гуманізоване антитіло до cd134 (ox40) і його застосування
KR102564207B1 (ko) 2013-08-08 2023-08-10 싸이튠 파마 Ｉｌ―１５ 및 ｉｌ―１５ｒ 알파 스시 도메인 기반 모듈로카인
BR112016013963A2 (pt) 2013-12-17 2017-10-10 Genentech Inc terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1
CA2943834A1 (en) 2014-03-31 2015-10-08 Genentech, Inc. Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
BR112017009151A2 (pt) 2014-11-03 2018-03-06 Genentech, Inc. ensaios para detectar subgrupos imunológicos de célula t e métodos de uso dos mesmos
WO2016073380A1 (en) * 2014-11-03 2016-05-12 Genentech, Inc. Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
CN107073126A (zh) 2014-11-06 2017-08-18 豪夫迈·罗氏有限公司 包含ox40结合激动剂和tigit抑制剂的组合疗法
KR20170096112A (ko) 2014-11-17 2017-08-23 제넨테크, 인크. Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
HUE048532T2 (hu) * 2015-01-08 2020-07-28 BioNTech SE Agonista TNF receptor kötõ ágensek
KR102435324B1 (ko) 2015-01-20 2022-08-23 아이쥐엠 바이오사이언스 인코포레이티드 종양 괴사 인자(ｔｎｆ) 수퍼패밀리 수용체 결합 분자 및 그의 용도
FI3265123T3 (fi) 2015-03-03 2023-01-31 Vasta-aineita, käyttöjä & menetelmiä
EP3268037B1 (en) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Cd27 agonists
HK1247630A1 (zh) * 2015-03-11 2018-09-28 Providence Health & Services-Oregon 用於增强癌症治疗的效果的组合物和方法
WO2016164480A1 (en) 2015-04-07 2016-10-13 Genentech, Inc. Antigen binding complex having agonistic activity and methods of use
PH12017502013B1 (en) 2015-05-07 2022-07-22 Agenus Inc Anti-ox40 antibodies and methods of use thereof
JP6797137B2 (ja) 2015-05-29 2020-12-09 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｏｘ４０に対する抗体およびその使用
AU2016291817A1 (en) 2015-07-16 2018-02-22 Biolinerx Ltd. Compositions and methods for treating cancer
WO2017046746A1 (en) 2015-09-15 2017-03-23 Acerta Pharma B.V. Therapeutic combinations of a btk inhibitor and a gitr binding molecule, a 4-1bb agonist, or an ox40 agonist
AU2016329120B2 (en) 2015-10-02 2023-04-13 F. Hoffmann-La Roche Ag Bispecific antibodies specific for a costimulatory TNF receptor
EP3363816A4 (en) * 2015-10-15 2019-10-09 Dingfu Biotarget Co., Ltd. ANTI-OX40 ANTIBODIES AND USES THEREOF
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
SG11201804265XA (en) 2015-12-02 2018-06-28 Agenus Inc Antibodies and methods of use thereof
SG10201601719RA (en) 2016-03-04 2017-10-30 Agency Science Tech & Res Anti-LAG-3 Antibodies
DE102016105069A1 (de) 2016-03-18 2017-09-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Antivirale Immuntherapie durch Membranrezeptorligation
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
CA3026474A1 (en) 2016-06-20 2017-12-28 Kymab Limited Anti-pd-l1 and il-2 cytokines
EP3487533A4 (en) * 2016-07-20 2020-03-25 IGM Biosciences, Inc. MULTIMERE OX40-BINDING MOLECULES AND USES THEREOF
EP3494139B1 (en) 2016-08-05 2022-01-12 F. Hoffmann-La Roche AG Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
CN107815465B (zh) 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
WO2018041119A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric ox40
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
EP3565888A1 (en) 2017-01-06 2019-11-13 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists
WO2018150326A1 (en) 2017-02-15 2018-08-23 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
JP2020522516A (ja) 2017-06-05 2020-07-30 アイオバンス バイオセラピューティクス，インコーポレイテッド 二重抵抗性黒色腫において腫瘍浸潤リンパ球を使用する方法
WO2019028182A2 (en) * 2017-08-01 2019-02-07 Remd Biotherapeutics, Inc. TREATMENT OF CANCER USING ANTIBODIES BINDING TO THE HUMAN CD134 RECEPTOR (OX40)
EP3704159A1 (en) 2017-11-01 2020-09-09 Bristol-Myers Squibb Company Immunostimulatory agonistic antibodies for use in treating cancer
AU2018368786B2 (en) 2017-11-17 2025-05-22 Iovance Biotherapeutics, Inc. TIL expansion from fine needle aspirates and small biopsies
WO2019106605A1 (en) 2017-12-01 2019-06-06 Board Of Regents, The University Of Texas System Combination treatment for cancer
TWI742336B (zh) * 2017-12-29 2021-10-11 圓祥生命科技股份有限公司 調節免疫檢查點作為癌症治療的單特異性與雙特異性蛋白質、其醫藥組成物、其核酸、及其用途
KR20200119242A (ko) 2018-01-08 2020-10-19 이오반스 바이오테라퓨틱스, 인크. 종양 항원-특이적 t-세포에 대해 풍부화된 til 생성물의 생성 방법
WO2019136459A1 (en) 2018-01-08 2019-07-11 Iovance Biotherapeutics, Inc. Processes for generating til products enriched for tumor antigen-specific t-cells
US11713446B2 (en) 2018-01-08 2023-08-01 Iovance Biotherapeutics, Inc. Processes for generating TIL products enriched for tumor antigen-specific T-cells
CN111393529B (zh) * 2018-01-29 2022-02-22 康源博创生物科技(北京)有限公司 与ox40l非竞争结合的抗ox40抗体
MA51875A (fr) 2018-02-13 2020-12-23 Iovance Biotherapeutics Inc Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine
TW202003555A (zh) 2018-03-07 2020-01-16 英商葛蘭素史克智慧財產發展有限公司 用於純化重組多肽之方法
KR102761890B1 (ko) 2018-03-23 2025-02-06 브리스톨-마이어스 스큅 컴퍼니 Mica 및/또는 micb에 대한 항체 및 그의 용도
WO2019191133A1 (en) 2018-03-27 2019-10-03 Bristol-Myers Squibb Company Real-time monitoring of protein concentration using ultraviolet signal
CN108753733B (zh) * 2018-04-11 2022-03-25 南京泰斯德生物科技有限公司 杂交瘤细胞株及其产生的抗糖基单克隆抗体以及制备方法与制剂
TW202446952A (zh) 2018-04-27 2024-12-01 美商艾歐凡斯生物治療公司 腫瘤浸潤性淋巴細胞之基因編輯和彼於免疫治療之用途
EP4074732A1 (en) * 2018-05-11 2022-10-19 Wuxi Biologics (Shanghai) Co. Ltd. Fully human antibodies against ox40, method for preparing the same, and use thereof
MX2020012567A (es) 2018-05-23 2021-01-29 Beigene Ltd Anticuerpos anti-ox40 y metodos de uso.
AU2019287765A1 (en) 2018-06-15 2021-01-07 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
GB201811410D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
US20210277135A1 (en) 2018-07-13 2021-09-09 Bristol-Myers Squibb Company Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor
TW202031273A (zh) 2018-08-31 2020-09-01 美商艾歐凡斯生物治療公司 抗ｐｄ－１抗體難治療性之非小細胞肺癌（ｎｓｃｌｃ）病患的治療
SG11202101787XA (en) 2018-09-20 2021-04-29 Iovance Biotherapeutics Inc Expansion of tils from cryopreserved tumor samples
EP3858857A1 (en) 2018-09-26 2021-08-04 Jiangsu Hengrui Medicine Co., Ltd. An anti-ox40 antibody, antigen-binding fragment thereof, and the pharmaceutical use
EP3874024A1 (en) 2018-10-31 2021-09-08 Juno Therapeutics GmbH Methods for selection and stimulation of cells and apparatus for same
CN113272421B (zh) 2018-11-05 2025-02-18 艾欧凡斯生物治疗公司 用于产生肿瘤浸润性淋巴细胞的方法及其在免疫疗法中的用途
ES3021682T3 (en) 2018-11-05 2025-05-27 Iovance Biotherapeutics Inc Tumour infiltrating lymphocytes for use in treating nsclc patients refractory to anti-pd-1 antibodies
JP2022506508A (ja) 2018-11-05 2022-01-17 アイオバンス バイオセラピューティクス，インコーポレイテッド Ａｋｔ経路阻害剤を利用したｔｉｌの拡大培養
MX2021004953A (es) 2018-11-05 2021-08-11 Iovance Biotherapeutics Inc Seleccion de celulas t reactivas al tumor mejoradas.
WO2020097132A1 (en) 2018-11-06 2020-05-14 Juno Therapeutics, Inc. Process for producing genetically engineered t cells
US20220193131A1 (en) 2018-12-19 2022-06-23 Iovance Biotherapeutics, Inc. Methods of Expanding Tumor Infiltrating Lymphocytes Using Engineered Cytokine Receptor Pairs and Uses Thereof
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
WO2020205662A1 (en) 2019-03-29 2020-10-08 Myst Therapeutics, Inc. Ex vivo methods for producing a t cell therapeutic and related compositions and methods
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
WO2020232029A1 (en) 2019-05-13 2020-11-19 Iovance Biotherapeutics, Inc. Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy
WO2020237221A1 (en) 2019-05-23 2020-11-26 Bristol-Myers Squibb Company Methods of monitoring cell culture media
CN114127315A (zh) 2019-05-30 2022-03-01 百时美施贵宝公司 鉴定适合于免疫肿瘤学(i-o)疗法的受试者的方法
WO2020243563A1 (en) 2019-05-30 2020-12-03 Bristol-Myers Squibb Company Multi-tumor gene signatures for suitability to immuno-oncology therapy
JP2022534981A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよび組み合わせ治療
CN114040776B (zh) * 2019-06-28 2024-05-14 江苏恒瑞医药股份有限公司 Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途
CA3155727A1 (en) 2019-10-25 2021-04-29 Cecile Chartier-Courtaud Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy
WO2021084050A1 (en) 2019-10-30 2021-05-06 Juno Therapeutics Gmbh Cell selection and/or stimulation devices and methods of use
CN118320076A (zh) * 2019-11-21 2024-07-12 百济神州有限公司 使用抗ox40抗体与抗tim3抗体的组合治疗癌症的方法
EP4061844A4 (en) * 2019-11-21 2023-12-06 Beigene (Beijing) Co., Ltd. Methods of cancer treatment with anti-ox40 antibody in combination with chemotherapeutic agents
KR20220122639A (ko) 2019-11-27 2022-09-02 미스트 쎄라퓨틱스, 엘엘씨 조절제를 이용한 종양 반응성 t 세포 조성물의 제조 방법
CA3161104A1 (en) 2019-12-11 2021-06-17 Cecile Chartier-Courtaud Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CN114867749A (zh) 2019-12-17 2022-08-05 安进公司 用于疗法中的双重白介素-2/tnf受体激动剂
KR20220158727A (ko) 2020-02-27 2022-12-01 미스트 쎄라퓨틱스, 엘엘씨 종양 반응성 t 세포의 생체외 농축 및 확장 방법 및 이의 관련 조성물
TWI873313B (zh) * 2020-03-23 2025-02-21 大陸商百奧泰生物製藥股份有限公司 一種免疫細胞啟動劑的開發及應用
EP4146793A1 (en) 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Selection of improved tumor reactive t-cells
CA3176826A1 (en) 2020-05-04 2021-11-11 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
CN111518209B (zh) * 2020-05-09 2023-07-25 郑州航空港百桥生物科技有限公司 特异性结合人ox40的单克隆抗体及其应用
US20230181641A1 (en) 2020-05-13 2023-06-15 Juno Therapeutics, Inc. Process for producing donor-batched cells expressing a recombinant receptor
CA3184366A1 (en) 2020-06-29 2022-01-06 Darby Rye Schmidt Viruses engineered to promote thanotransmission and their use in treating cancer
MX2023002326A (es) 2020-08-31 2023-03-21 Bristol Myers Squibb Co Firma de localizacion celular e inmunoterapia.
CN116406369A (zh) 2020-10-05 2023-07-07 百时美施贵宝公司 用于浓缩蛋白质的方法
JP2023546359A (ja) 2020-10-06 2023-11-02 アイオバンス バイオセラピューティクス，インコーポレイテッド 腫瘍浸潤リンパ球療法によるｎｓｃｌｃ患者の治療
WO2022076606A1 (en) 2020-10-06 2022-04-14 Iovance Biotherapeutics, Inc. Treatment of nsclc patients with tumor infiltrating lymphocyte therapies
CN112794907B (zh) * 2020-12-03 2022-09-06 安徽安科生物工程（集团）股份有限公司 一株全人源抗人huOX40单克隆抗体
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
JP2024501452A (ja) 2020-12-11 2024-01-12 アイオバンス バイオセラピューティクス，インコーポレイテッド Ｂｒａｆ阻害剤及び／またはｍｅｋ阻害剤と併用した腫瘍浸潤リンパ球治療によるがん患者の治療
CA3202483A1 (en) 2020-12-17 2022-06-23 Maria Fardis Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors
US20240123067A1 (en) 2020-12-17 2024-04-18 Iovance Biotherapeutics, Inc. Treatment of cancers with tumor infiltrating lymphocyte therapies
WO2022146948A1 (en) 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Subcutaneous administration of pd1/pd-l1 antibodies
AU2021411486A1 (en) 2020-12-28 2023-06-29 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
JP2024512669A (ja) 2021-03-31 2024-03-19 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド タノトランスミッションポリペプチド及び癌の処置におけるそれらの使用
US20240376224A1 (en) 2021-04-02 2024-11-14 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
IL307800A (en) 2021-04-19 2023-12-01 Iovance Biotherapeutics Inc Chimeric costimulatory receptors, chemokine receptors and their use in cellular immunotherapy
EP4334341A2 (en) 2021-05-06 2024-03-13 Juno Therapeutics GmbH Methods for stimulating and transducing t cells
JP2024527334A (ja) * 2021-06-29 2024-07-24 ハイファイバイオ（ホンコン）リミテッド 抗ｏｘ４０モノクローナル抗体及びその使用方法
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
TW202327631A (zh) 2021-07-28 2023-07-16 美商艾歐凡斯生物治療公司 利用腫瘤浸潤性淋巴球療法與ｋｒａｓ抑制劑組合治療癌症患者
WO2023077015A2 (en) 2021-10-27 2023-05-04 Iovance Biotherapeutics, Inc. Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy
WO2023086803A1 (en) 2021-11-10 2023-05-19 Iovance Biotherapeutics, Inc. Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes
EP4469066A1 (en) 2022-01-28 2024-12-04 Iovance Biotherapeutics, Inc. Tumor infiltrating lymphocytes engineered to express payloads
WO2023152116A1 (en) 2022-02-08 2023-08-17 Hookipa Biotech Gmbh Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines
KR20240156411A (ko) 2022-03-09 2024-10-29 브리스톨-마이어스 스큅 컴퍼니 치료 단백질의 일시적 발현
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023201369A1 (en) 2022-04-15 2023-10-19 Iovance Biotherapeutics, Inc. Til expansion processes using specific cytokine combinations and/or akti treatment
WO2023213969A1 (en) 2022-05-05 2023-11-09 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
US20250332252A1 (en) 2022-06-02 2025-10-30 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024030758A1 (en) 2022-08-01 2024-02-08 Iovance Biotherapeutics, Inc. Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies
EP4583999A1 (en) 2022-09-09 2025-07-16 Bristol-Myers Squibb Company Methods of separating chelator
EP4598946A1 (en) 2022-10-05 2025-08-13 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
CN121100267A (zh) 2022-12-09 2025-12-09 朱诺治疗学股份有限公司 使用全息成像预测细胞表型的机器学习方法
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer
WO2024151885A1 (en) 2023-01-13 2024-07-18 Iovance Biotherapeutics, Inc. Use of til as maintenance therapy for nsclc patients who achieved pr/cr after prior therapy
CN121002052A (zh) 2023-02-03 2025-11-21 C3S2 有限公司 用于非病毒生产工程化免疫细胞的方法
WO2024196952A1 (en) 2023-03-20 2024-09-26 Bristol-Myers Squibb Company Tumor subtype assessment for cancer therapy
WO2025021131A1 (en) * 2023-07-25 2025-01-30 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Methods of treating alopecia areata and atopic dermatitis
WO2025038763A1 (en) 2023-08-15 2025-02-20 Bristol-Myers Squibb Company Ceramic hydroxyapatite chromatography flow through method
WO2025101484A1 (en) 2023-11-06 2025-05-15 Iovance Biotherapeutics, Inc. Treatment of endometrial cancers with tumor infiltrating lymphocyte therapies
WO2025145207A1 (en) 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
WO2025162471A1 (en) * 2024-01-30 2025-08-07 Hanx Biopharmaceuticals, (Wuhan) Ltd. Antibodies and antibody-drug conjugates targeting ox40 and uses thereof

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
ES2227512T3 (es) 1991-12-02 2005-04-01 Medical Research Council Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago.
JPH08500962A (ja) 1992-02-06 1996-02-06 クリエイティブ バイオモレキュルズ，インコーポレイテッド 癌マーカー用生物合成結合蛋白質
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ATE204325T1 (de) 1993-04-29 2001-09-15 Unilever Nv Herstellung von antikörpern oder funktionstüchtig gemachten teilen davon, abgeleitet von schweren ketten von immunglobulinen von camelidae
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US7473423B2 (en) 1994-04-29 2009-01-06 Mayo Foundation For Medical Education And Research Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
US5463564A (en) 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
US5504004A (en) 1994-12-20 1996-04-02 Michigan Biotechnology Institute Process for making succinic acid, microorganisms for use in the process and methods of obtaining the microorganisms
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ES2315008T5 (es) 1998-02-24 2012-03-06 Sisters Of Providence In Oregon Agente de unión a receptor ox-40 para su uso en métodos de mejora de la respuesta inmune espec�?fica de ant�?geno tumoral.
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20020004041A1 (en) 1999-02-19 2002-01-10 Albert Matthew L. Methods for abrogating a cellular immune response
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US7550140B2 (en) 2002-06-13 2009-06-23 Crucell Holland B.V. Antibody to the human OX40 receptor
EP2135879A3 (en) * 2002-06-28 2010-06-23 Domantis Limited Ligand
WO2004111233A1 (ja) 2003-06-11 2004-12-23 Chugai Seiyaku Kabushiki Kaisha 抗体の製造方法
US20080008719A1 (en) 2004-07-10 2008-01-10 Bowdish Katherine S Methods and compositions for the treatment of prostate cancer
EP1814568A4 (en) 2004-10-29 2009-08-12 Univ Southern California COMBINATION IMMUNOTHERAPY AGAINST CANCER WITH COSTIMULATORY MOLECULES
WO2006055697A2 (en) 2004-11-17 2006-05-26 Board Of Regents, The University Of Texas System Cancer immunotherapy incorporating p53
EP1844073A1 (en) 2005-01-31 2007-10-17 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
US7189097B2 (en) 2005-02-11 2007-03-13 Winchester Electronics Corporation Snap lock connector
DK3050963T3 (da) 2005-03-31 2019-12-09 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
US20080194596A1 (en) 2005-06-03 2008-08-14 Frizer Inc. Therapeutic Combination Including a Selective Erbb2 Inhibitor
US8324194B2 (en) 2005-11-22 2012-12-04 Incyte Corporation Combination therapy for the treatment of cancer
TWI461436B (zh) 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
US20070255631A1 (en) 2005-11-28 2007-11-01 Douglas Schmidt Product catalog management system and method
KR101866623B1 (ko) 2005-11-28 2018-07-04 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
EP1999154B1 (en) 2006-03-24 2012-10-24 Merck Patent GmbH Engineered heterodimeric protein domains
US20110028688A1 (en) 2006-06-21 2011-02-03 Genentech, Inc. Crystal structure of ox40l and ox40l complexed with ox40 receptor
MX2009009194A (es) 2007-02-27 2009-10-08 Genentech Inc Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes.
CA2681974C (en) 2007-03-29 2019-12-31 Genmab A/S Bispecific antibodies and methods for production thereof
US8748356B2 (en) 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
ES2425269T3 (es) 2007-12-14 2013-10-14 Bristol-Myers Squibb Company Moléculas de unión al receptor OX40 humano
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CA2722466A1 (en) 2008-04-29 2009-11-05 Tariq Ghayur Dual variable domain immunoglobulins and uses thereof
US8652843B2 (en) 2008-08-12 2014-02-18 Oncomed Pharmaceuticals, Inc. DDR1-binding agents and methods of use thereof
JP2012505654A (ja) 2008-10-14 2012-03-08 ヤンセン バイオテツク，インコーポレーテツド 抗体をヒト化及び親和性成熟する方法
US8614295B2 (en) 2009-02-17 2013-12-24 Ucb Pharma S.A. Antibody molecules having specificity for human OX40
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
ES2609043T3 (es) 2009-11-30 2017-04-18 Janssen Biotech, Inc. Anticuerpos mutantes Fc con funciones de efecto abladas
CN102763158A (zh) * 2010-02-11 2012-10-31 夏普株式会社 图像处理器、显示装置及图像处理方法
PL2560993T3 (pl) 2010-04-20 2024-11-04 Genmab A/S Heterodimeryczne białka zawierające region FC przeciwciała i sposoby ich wytwarzania
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
ME02678B (me) 2010-08-23 2017-06-20 Univ Texas Antitijela na ox-40 i postupci njihove primjene
RS59589B1 (sr) 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
EA036047B1 (ru) 2011-07-11 2020-09-18 Икнос Сайенсиз Са Антитела, которые связываются с ox40, и их применение
GB201116092D0 (en) 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
UA119319C2 (uk) * 2013-03-18 2019-06-10 Біосерокс Продактс Б.В. Гуманізоване антитіло до cd134 (ox40) і його застосування

Also Published As

Publication number Publication date
WO2013038191A2 (en) 2013-03-21
MD20170082A2 (ro) 2018-02-28
CN104080809B (zh) 2017-05-17
SG11201400706SA (en) 2014-10-30
KR20140069172A (ko) 2014-06-09
AU2012308155A1 (en) 2014-04-03
CL2014000631A1 (es) 2014-09-26
MD4578C1 (ro) 2019-02-28
HK1201852A1 (en) 2015-09-11
JP2014527814A (ja) 2014-10-23
PH12014500598A1 (en) 2014-05-12
CL2016002816A1 (es) 2017-04-28
WO2013038191A3 (en) 2013-07-18
JP6212493B2 (ja) 2017-10-11
NZ623840A (en) 2016-04-29
CO7020859A2 (es) 2014-08-11
NZ718372A (en) 2018-09-28
MX2014003156A (es) 2014-08-22
PE20141546A1 (es) 2014-11-13
CN107722123A (zh) 2018-02-23
CA2848847A1 (en) 2013-03-21
MD4578B1 (ro) 2018-07-31
MX352495B (es) 2017-11-28
AU2017202564A1 (en) 2017-05-11
EA031006B1 (ru) 2018-10-31
US9475880B2 (en) 2016-10-25
EA201490484A1 (ru) 2014-09-30
ZA201502860B (en) 2016-11-30
MY185448A (en) 2021-05-19
CN104080809A (zh) 2014-10-01
IL231540A0 (en) 2014-04-30
EP3409689A1 (en) 2018-12-05
PH12019501115A1 (en) 2020-07-13
IL231540B (en) 2019-05-30
IN2014CN02535A (enExample) 2015-08-07
BR112014006158A2 (pt) 2017-04-04
US20170051069A1 (en) 2017-02-23
MD20140039A2 (ro) 2014-09-30
AU2012308155B2 (en) 2017-03-16
ECSP14013259A (es) 2014-05-31
US20180273632A1 (en) 2018-09-27
IL266608A (en) 2019-07-31
MD4612B1 (ro) 2019-01-31
ZA201401939B (en) 2016-08-31
HK1249909A1 (zh) 2018-11-16
EA201890934A1 (ru) 2019-02-28
GT201400051A (es) 2016-01-28
EP2756001A2 (en) 2014-07-23
MD4612C1 (ro) 2019-08-31
UA115316C2 (uk) 2017-10-25
SG10201608872VA (en) 2016-12-29
AU2017202564B2 (en) 2018-11-22
CR20140146A (es) 2014-07-02
US20150132288A1 (en) 2015-05-14

Similar Documents

Publication Publication Date Title
PH12019501115A1 (en) Anti-cd134 (ox40) antibodies and uses thereof
PH12015502185A1 (en) Humanized anti-cd134 (ox40) antibodies and uses thereof
MX2015004105A (es) Anticuerpos monoclonales humanos anti-pd-l1 y metodos de uso.
AU2011338480A8 (en) Humanized antibodies to LIV-1 and use of same to treat cancer
MX2013010268A (es) Anticuerpos anti-ctla4 humanizados.
TN2012000057A1 (en) Antibodies against the ectodomain of erbb3 and uses thereof
MX2014009751A (es) Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer.
WO2011088385A3 (en) Compositions and methods for detecting cancer
MX2014004326A (es) Anticuerpos a cd1d.
TH174505A (th) ฮิวเมไนซ์แอนติ-cd134 (ox40) แอนติบอดีและการใช้ของมัน
TH152457A (th) แอนติ-cd134 (ox40) แอนติบอดี และการใช้ของมัน
TR201905240T4 (tr) LIV-1'e hümanize edilmiş antikorlar ve bunların kanserin tedavisinde kullanımı.

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)